Immunocore's investigational immunotherapy and lead drug candidate, tebentafusp, will be fast-tracked through the EU review process when the company files for approval. Tebentafusp is a potential treatment for patients with previously untreated metastatic uveal melanoma, a rare and aggressive cancer of the eye.
Immunocore, Ltd.'s accelerated assessment request was the only one of five such applications that was granted at the June...








